158 related articles for article (PubMed ID: 27570681)
1. How Have Cancer Clinical Trial Eligibility Criteria Evolved Over Time?
Yaman A; Chakrabarti S; Sen A; Weng C
AMIA Jt Summits Transl Sci Proc; 2016; 2016():269-78. PubMed ID: 27570681
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Trend and Network Analysis of Common Eligibility Features for Cancer Trials in ClinicalTrials.gov.
Weng C; Yaman A; Lin K; He Z
Smart Health; 2014 Jul; 8549():130-141. PubMed ID: 26998530
[TBL] [Abstract][Full Text] [Related]
4. Enhancing reuse of structured eligibility criteria and supporting their relaxation.
Milian K; Hoekstra R; Bucur A; Ten Teije A; van Harmelen F; Paulissen J
J Biomed Inform; 2015 Aug; 56():205-19. PubMed ID: 26015310
[TBL] [Abstract][Full Text] [Related]
5. A knowledge base of clinical trial eligibility criteria.
Liu H; Chi Y; Butler A; Sun Y; Weng C
J Biomed Inform; 2021 May; 117():103771. PubMed ID: 33813032
[TBL] [Abstract][Full Text] [Related]
6. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
7. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
[TBL] [Abstract][Full Text] [Related]
8. Using a content analysis to identify study eligibility criteria concepts in cancer nursing research.
Guo JW; Sward K; Beck S; Wong B; Staggers N; Frey L
Comput Inform Nurs; 2014 Jul; 32(7):333-42. PubMed ID: 24814997
[TBL] [Abstract][Full Text] [Related]
9. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
10. Automatic trial eligibility surveillance based on unstructured clinical data.
Meystre SM; Heider PM; Kim Y; Aruch DB; Britten CD
Int J Med Inform; 2019 Sep; 129():13-19. PubMed ID: 31445247
[TBL] [Abstract][Full Text] [Related]
11. Clustering clinical trials with similar eligibility criteria features.
Hao T; Rusanov A; Boland MR; Weng C
J Biomed Inform; 2014 Dec; 52():112-20. PubMed ID: 24496068
[TBL] [Abstract][Full Text] [Related]
12. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
13. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
[TBL] [Abstract][Full Text] [Related]
14. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.
Srikanthan A; Vera-Badillo F; Ethier J; Goldstein R; Templeton AJ; Ocana A; Seruga B; Amir E
Cancer Treat Rev; 2016 Feb; 43():67-73. PubMed ID: 26827694
[TBL] [Abstract][Full Text] [Related]
15. Frequency analysis of medical concepts in clinical trials and their coverage in MeSH and SNOMED-CT.
Varghese J; Dugas M
Methods Inf Med; 2015; 54(1):83-92. PubMed ID: 25346408
[TBL] [Abstract][Full Text] [Related]
16. Impacts of Eligibility Criteria on Trial Participants' Age in Alzheimer's Disease Clinical Trials.
Chen A; Li Q; He X; Jaffee MS; Hogan WR; Wang F; Guo Y; Bian J
AMIA Annu Symp Proc; 2022; 2022():368-376. PubMed ID: 37128470
[TBL] [Abstract][Full Text] [Related]
17. Analysis of eligibility criteria representation in industry-standard clinical trial protocols.
Bhattacharya S; Cantor MN
J Biomed Inform; 2013 Oct; 46(5):805-13. PubMed ID: 23770150
[TBL] [Abstract][Full Text] [Related]
18. A method for probing disease relatedness using common clinical eligibility criteria.
Boland MR; Miotto R; Weng C
Stud Health Technol Inform; 2013; 192():481-5. PubMed ID: 23920601
[TBL] [Abstract][Full Text] [Related]
19. Unsupervised mining of frequent tags for clinical eligibility text indexing.
Miotto R; Weng C
J Biomed Inform; 2013 Dec; 46(6):1145-51. PubMed ID: 24036004
[TBL] [Abstract][Full Text] [Related]
20. Parsable Clinical Trial Eligibility Criteria Representation Using Natural Language Processing.
Kim J; Izower M; Quintana Y
AMIA Annu Symp Proc; 2022; 2022():616-624. PubMed ID: 37128426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
